STAAR Surgical Company
Income Statement
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | $322.4M | $239.4M | $230.5M | $150.2M | $124.0M | $90.6M |
| Cost of Revenue | $57.0M | $74.3M | $69.8M | $61.0M | $51.8M | $38.2M | $32.4M | $26.3M |
| Gross Profit | $182.4M | $239.6M | $252.7M | $223.4M | $178.6M | $112.0M | $91.5M | $64.3M |
| Gross Margin | 76.2% | 76.3% | 78.4% | 93.3% | 77.5% | 74.5% | 73.8% | 70.9% |
| Operating Expenses | ||||||||
| Research & Development | $40.1M | $45.3M | $40.5M | $36.0M | $33.9M | $25.3M | $22.0M | $20.0M |
| SG&A Expense | $274.1M | $252.2M | $224.6M | $179.6M | $145.3M | $100.1M | $84.9M | $67.9M |
| Operating Income | $-91.7M | $-12.6M | $28.1M | $43.8M | $33.3M | $11.9M | $6.6M | $-3.6M |
| Operating Margin | -38.3% | -4.0% | 8.7% | 18.3% | 14.5% | 7.9% | 5.3% | -4.0% |
| Interest Expense | — | — | — | — | — | — | — | $112.0K |
| Pretax Income | $-82.3M | $-9.1M | $33.7M | $45.6M | $31.3M | $13.0M | $6.6M | $-2.3M |
| Income Tax Expense | $-1.8M | $11.2M | $12.3M | $5.9M | $3.8M | $-1.0M | $1.7M | $-157.0K |
| Net Income | $-80.4M | $-20.2M | $21.3M | $39.7M | $27.5M | $14.0M | $5.0M | $-2.1M |
| Net Margin | -33.6% | -6.4% | 6.6% | 16.6% | 11.9% | 9.4% | 4.0% | -2.4% |
| EPS (Basic) | $-1.62 | $-0.41 | $0.44 | $0.83 | $0.58 | $0.32 | $0.12 | $-0.05 |
| EPS (Diluted) | $-1.62 | $-0.41 | $0.43 | $0.80 | $0.56 | $0.30 | $0.11 | $-0.05 |
| Shares Outstanding (Basic) | 49.6M | 49.1M | 48.5M | 48.0M | 47.2M | 44.5M | 42.6M | 41.0M |
| Shares Outstanding (Diluted) | 49.6M | 49.1M | 49.4M | 49.4M | 49.5M | 46.9M | 45.3M | 41.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |